Prednisolone in HBsAg-positive chronic active hepatitis: histologic evaluation in a controlled prospective study.
To study the value of corticosteroids in HBsAg-positive chronic active hepatitis, 18 pairs of liver histology comprising 36 liver biopsies from a prospective, randomized, controlled trial were evaluated. The median interval between the initial and follow-up histology was 8 1/2 months in 8 patients given prednisolone and 8 1/4 months in 10 patients given placebo tablets. Following medication, there was significantly greater erosion of the limiting plate in the prednisolone group (p = 0.039) accompanied by a larger quantity of HBsAg (p = 0.045) and HBcAg (p = 0.006) in the liver. We conclude that prednisolone causes immunosuppression permitting enhanced viral multiplication and leads to increased erosion of the limiting plate. Our result also indicates that progression to cirrhosis is unhalted by prednisolone therapy. The histologic findings support clinico-biochemical conclusion that the use of prednisolone is deleterious to patients with HBsAg-positive chronic active hepatitis.
D001706:Biopsy; D006512:Hepatitis B Core Antigens / Q000032:analysis; D006514:Hepatitis B Surface Antigens; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology*; D008115:Liver Regeneration; D011239:Prednisolone / Q000009:adverse effects*; D011446:Prospective Studies
D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens; D011239:Prednisolone